Structural Chemistry
The Structural Chemistry facility (led by Dr Amin Mirza) within the Centre for Cancer Drug Discovery is dedicated to providing analytical chemistry expertise, tools, and methodology for comprehensive structural elucidation in drug discovery.
We are responsible for the characterisation of all compounds synthesised in-house. This has included at least eight CTU drug discovery programmes which have, either alone or with commercial collaborators, progressed to Phase I clinical stage or beyond.
Our capabilities include:
Small Molecules Characterisation
The facility ensures provision of open-access structural, molecular weight, and purity assay by NMR and LC/MS
We deliver expert structure elucidation using state of the art instrumentation extending to isolation and characterisation of significant metabolites
We provide systems and expertise for monitoring the integrity and stability of the CTUs small molecule and fragment libraries
|
Separation & Purification
The facility ensures provision of systems and support for open-access preparative systems
We deliver expert method development for analytical, chiral, and preparative chromatography
|
PhysChem Properties Determination
We deliver method development and support of assays for kinetic solubility and LogD by HPLC
We provide quantitative NMR protocols for solubility and concentration determination
|
Protein and Ligand Interactions
We provide online mass spectrometry of intact proteins and peptides, characterisation of PTMs, and investigations of native structure
The facility delivers expertise for development of orthogonal mass spectrometry or NMR based protein/peptide-ligand interaction screening assay technologies
|